According to a UK university, researchers have identified 42 genes associated with increased risk of Alzheimer's disease.

The research published in the journal Nature Genetics informed that the genome of more than 100,000 people with Alzheimer’s disease were studied and it was compared with 600,000 healthy individuals in order to find out more about genetic makeup.

"This study more than doubles the number of identified genes influencing risk for the more common form of Alzheimer’s disease," Dr Rebecca Sims, co-leader of the study said.

<a href="https://www.wionews.com/entertainment/lifestyle/news-change-in-age-related-sleep-pattern-could-be-early-signs-of-dementia-states-new-study-409655">Also Read: Sleeping for long hours may be early sign of Alzheimer’s disease: Study&nbsp;</a>

The study showed specific biological signalling pathway involving TNF-alpha, a protein which plays an important role in the "inflammation and the immune system" was "implicated in Alzheimer's".

The study also found "dysfunction of microglia, immune cells in the brain that are responsible for eliminating toxic substances that contribute to disease pathology."

The study is considered a breakthrough in dementia research as scientists study how likely patients with cognitive impairment may&nbsp;develop Alzheimer's within three years of first showing symptoms.

Watch:&nbsp;US approves new drug to treat Alzheimer's disease

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/united-states-approves-new-drug-to-treat-alzheimers-disease-390063/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Although the current research is not intended to be used in clinical practice, however, the report said researchers hope it would help to improve the evaluation of new drugs in clinical trials.

The research hopes to identify people who have the greatest risk of developing Alzheimer's before they develop the condition and also broaden studies on demographics since the present study is primarily conducted on Caucasian populations.&nbsp;

The worldwide study involved genome samples from the EU, Argentina, New Zealand, UK, US, Canada, Iceland, Australia and Brazil.

(With inputs from Agencies)

According to a UK university, researchers have identified 42 genes associated with increased risk of Alzheimer's disease. The research published in the journal Nature Genetics informed that the genome of more than 100,000 people with Alzheimer’s disease were studied and it was compared with 600,000 healthy individuals in order to find out more about genetic makeup.

According to a UK university, researchers have identified 42 genes associated with increased risk of Alzheimer's disease. The research published in the journal Nature Genetics informed that the genome of more than 100,000 people with Alzheimer’s disease were studied and it was compared with 600,000 healthy individuals in order to find out more about genetic makeup. "This study more than doubles the number of identified genes influencing risk for the more common form of Alzheimer’s disease," Dr Rebecca Sims, co-leader of the study said. Also Read: Sleeping for long hours may be early sign of Alzheimer’s disease: Study The study showed specific biological signalling pathway involving TNF-alpha, a protein which plays an important role in the "inflammation and the immune system" was "implicated in Alzheimer's". The study also found "dysfunction of microglia, immune cells in the brain that are responsible for eliminating toxic substances that contribute to disease pathology." The study is considered a breakthrough in dementia research as scientists study how likely patients with cognitive impairment may develop Alzheimer's within three years of first showing symptoms. Watch: US approves new drug to treat Alzheimer's disease Although the current research is not intended to be used in clinical practice, however, the report said researchers hope it would help to improve the evaluation of new drugs in clinical trials. The research hopes to identify people who have the greatest risk of developing Alzheimer's before they develop the condition and also broaden studies on demographics since the present study is primarily conducted on Caucasian populations. The worldwide study involved genome samples from the EU, Argentina, New Zealand, UK, US, Canada, Iceland, Australia and Brazil. (With inputs from Agencies)

In major breakthrough, study discovers 42 new genes linked to increased risk of Alzheimer’s disease

The US Foods and Drug Administration(FDA) on Monday approved Biogen's aducanumab drug for Alzheimer's patience.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Breaking news: The FDA has approved Aducanumab, the first FDA-approved drug that delays decline due to Alzheimer’s. On behalf of those impacted by Alzheimer’s &amp; all other dementia, we celebrate today’s historic decision. <a href="https://t.co/2oJIeMADog">pic.twitter.com/2oJIeMADog</a>
— Alzheimer's Association (@alzassociation) <a href="https://twitter.com/alzassociation/status/1401922061816287236?ref_src=twsrc%5Etfw">June 7, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The FDA said: "There is substantial evidence that aducanumab reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients."

However, the US drug regulator did say that "aducanumab data" is "complicated" with respect to its clinical benefits.

During Alzheimer's a patient suffers from memory loss and is unable to take care of himself, the drug reportedly aims to remove amyloid beta from the brains of patients in the early stages of the disease.

However, the FDA asserted that if the drug does not work it could remove it. The regulator has given&nbsp;"Accelerated Approval" to the drug since it believes it benefits patients over existing treatments but there is still some uncertainty.

The FDA hasn't approved a single Alzheimer’s drug since 2003.

The drug however has produced mixed results. In 2019, the company had halted trials after a committee said the drug didn't show any results, however, the company last year said that it worked when a patient was given a higher dose.

"As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives," FDA's Patrizia Cavazzoni said.

Other companies including Pfizer and Johnson &amp; Johnson had earlier scrapped their study including Merck whose trials failed four years ago. Eli Lilly and Roche also failed to make an impact with their drugs.

There are reportedly 6 million people in the US who suffer from Alzheimer's.

(With inputs from Agencies)

The US Foods and Drug Administration(FDA) on Monday approved Biogen's aducanumab drug for Alzheimer's patience. Breaking news: The FDA has approved Aducanumab, the first FDA-approved drug that delays decline due to Alzheimer’s.

The US Foods and Drug Administration(FDA) on Monday approved Biogen's aducanumab drug for Alzheimer's patience. Breaking news: The FDA has approved Aducanumab, the first FDA-approved drug that delays decline due to Alzheimer’s. On behalf of those impacted by Alzheimer’s & all other dementia, we celebrate today’s historic decision. pic.twitter.com/2oJIeMADog — Alzheimer's Association (@alzassociation) June 7, 2021 × The FDA said: "There is substantial evidence that aducanumab reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients." However, the US drug regulator did say that "aducanumab data" is "complicated" with respect to its clinical benefits. During Alzheimer's a patient suffers from memory loss and is unable to take care of himself, the drug reportedly aims to remove amyloid beta from the brains of patients in the early stages of the disease. However, the FDA asserted that if the drug does not work it could remove it. The regulator has given "Accelerated Approval" to the drug since it believes it benefits patients over existing treatments but there is still some uncertainty. The FDA hasn't approved a single Alzheimer’s drug since 2003. The drug however has produced mixed results. In 2019, the company had halted trials after a committee said the drug didn't show any results, however, the company last year said that it worked when a patient was given a higher dose. "As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives," FDA's Patrizia Cavazzoni said. Other companies including Pfizer and Johnson & Johnson had earlier scrapped their study including Merck whose trials failed four years ago. Eli Lilly and Roche also failed to make an impact with their drugs. There are reportedly 6 million people in the US who suffer from Alzheimer's. (With inputs from Agencies)

In major breakthrough, US FDA approves new Alzheimer's drug

According to researchers, changes in the texture of the retina may help to detect&nbsp;Alzheimer’s disease.

Watch:

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/inside-french-village-constructed-for-alzheimers-patients-332094/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

The early detection of changes in the retina through the latest imaging technique may help health officials to fight the disease, a recent study has claimed. Alzheimer’s&nbsp;is the most common cause of dementia, accounting for 60 per cent to 80 per cent of cases in America.

According to a report, Alzheimer which becomes worse with time is thought to begin 20 years or more before symptoms arise. The symptoms occur when nerve cells in parts of the brain involved in thinking, learning and memory get damaged or destroyed.

Difficulty in remembering recent conversations, names or events is often an early clinical symptom, according to Alzheimer's Association report.

Dementia due to Alzheimer’s disease is characterised by noticeable memory, thinking or behavioural symptoms that impair a person’s ability to function in daily life, along with evidence of Alzheimer’s-related brain changes, the Alzheimer's Association claims.

Scientists have now unveiled the mouse model of Alzheimer’s which can potentially detect Alzheimer’s early and help in slowing the progress of the disease. &nbsp;The "non-invasive approach to identify measurable changes that will aid in clinical diagnostics", the study has said.

According to the report, there are currently 5.8 million Americans living with Alzheimer’s with the disease recently becoming the sixth largest cause of death in the US.

The study said layer-specific differences between pathological and control retinas are consistent with the known morphological changes associated with Alzheimer’s pathology.&nbsp;

"The data trends revealed in this study have a potential to serve as biomarkers of Alzheimer’s and with further development, may enable better identification of&nbsp;Alzheimer’s in human patients," it said.

According to researchers, changes in the texture of the retina may help to detect Alzheimer’s disease. Watch: The early detection of changes in the retina through the latest imaging technique may help health officials to fight the disease, a recent study has claimed.

According to researchers, changes in the texture of the retina may help to detect Alzheimer’s disease. Watch: The early detection of changes in the retina through the latest imaging technique may help health officials to fight the disease, a recent study has claimed. Alzheimer’s is the most common cause of dementia, accounting for 60 per cent to 80 per cent of cases in America. According to a report, Alzheimer which becomes worse with time is thought to begin 20 years or more before symptoms arise. The symptoms occur when nerve cells in parts of the brain involved in thinking, learning and memory get damaged or destroyed. Difficulty in remembering recent conversations, names or events is often an early clinical symptom, according to Alzheimer's Association report. Dementia due to Alzheimer’s disease is characterised by noticeable memory, thinking or behavioural symptoms that impair a person’s ability to function in daily life, along with evidence of Alzheimer’s-related brain changes, the Alzheimer's Association claims. Scientists have now unveiled the mouse model of Alzheimer’s which can potentially detect Alzheimer’s early and help in slowing the progress of the disease. The "non-invasive approach to identify measurable changes that will aid in clinical diagnostics", the study has said. According to the report, there are currently 5.8 million Americans living with Alzheimer’s with the disease recently becoming the sixth largest cause of death in the US. The study said layer-specific differences between pathological and control retinas are consistent with the known morphological changes associated with Alzheimer’s pathology. "The data trends revealed in this study have a potential to serve as biomarkers of Alzheimer’s and with further development, may enable better identification of Alzheimer’s in human patients," it said.

How changes in texture of retina may reveal signs of Alzheimer's disease

alzheimers-in-us

Alzheimer's In Us, News on Alzheimer's In Us, stories on Alzheimer's In Us, articles on Alzheimer's In Us, Alzheimer's In Us stories at Wion, Alzheimer's In Us news, Alzheimer's In Us latest news

alzheimers in-us

In major breakthrough, study discovers 42 new genes linked to increased risk of Alzheimer’s disease

In major breakthrough, US FDA approves new Alzheimer's drug

How changes in texture of retina may reveal signs of Alzheimer's disease